Menu

For UK Healthcare Professionals

 

DOSING

Packaging and storage

  • Starting the regimen

    There are two ways to start a patient on VOCABRIA + REKAMBYS:

    1. Optional Oral Lead-In

    2. Directly to Injections

    Optional oral lead-in can be used to assess tolerability. Prescribe 1 cabotegravir (30mg) and 1 rilpivirine (25mg) tablet. Both tablets are to be taken together with a meal at the same time each day, for at least 28 days.1

    VOCABRIA + REKAMBYS injections should be initiated on the final day of optional oral lead-in (Day 28).1

    Alternatively, patients can start directly on injections without the need for an oral lead-in.1

    Packaging

  • Injection pack contents

    Injection pack contents
    INJECTIONS ARE DOSED IN COMBINATION

    For administration of VOCABRIA + REKAMBYS, you will also need the following supplies, which are not included in the packs:1,2

    • Non-sterile gloves
    • 4 alcohol swabs
    • 2 gauze pads
    • A suitable sharps container

How to store VOCABRIA + REKAMBYS

Whilst VOCABRIA doesn’t require any special storage conditions, it is important to note that REKAMBYS must be stored in the refrigerator.1,2

  • VOCABRIA¹

    • Vials do not require any special storage conditions
    • Do not freeze
    • Use the medication as soon as possible after drawing it into the syringe
      • The drawn medication must be used within 2 hours and must stay below 25°C

  • REKAMBYS²

    • Vials must be stored in a refrigerator at 2°C to 8°C
    • Do not freeze
    • Prior to injection, allow at least 15 minutes for the vial contents to come to room temperature naturally (below 25°C)
    • Once the vial has been removed from the refrigerator, it cannot be re-refrigerated and must be used within 6 hours (maximum temperature 25°C) or discarded
    • Use the medication as soon as possible after drawing it into the syringe
      • The drawn medication must be used within 2 hours and must stay below 25°C

Colleague Testimonials

Hear what colleagues say about their experiences with long-acting therapy

References:

  1. VOCABRIA Summary of Product Characteristics. ViiV Healthcare.
  2. REKAMBYS Summary of Product Characteristics. Janssen Healthcare.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.

REKAMBYS (rilpivirine long acting injection), including the trademark is owned by the Janssen Pharmaceutical Companies and used under license by the ViiV Healthcare group of companies. All other trademarks are owned by the ViiV Healthcare group.

PM-GB-CBR-WCNT-210001v3 I April 2022

Prescribing Information

Report an adverse event

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221441.

If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.